stockrowInhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024.
- Revenue
- +992.4%
- EPS
- −26.5%
- Free cash flow
- +0.12%
- Total debt
- +77.6%
Quarter to June 2026, against a year earlier
Follow INBX
Alert me
Inhibrx Biosciences, Inc. (INBX) EV/Sales
As of 6 November 2026, Inhibrx Biosciences, Inc. (INBX) trades at a EV/Sales of 439×. Over the past ten years it has ranged from 0.0× (June 2024) to 706× (May 2026); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 381× | 165.70% |
| FY2024 | 143× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 42.3× | (70.45%) |
| Dec 2024 | 143× | 50.46% |
| Jun 2024 | 95.2× | — |
| Dec 2023 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| SGP SpyGlass Pharma, Inc. compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| MNKD MannKind Corporation compare | 3.8× |
| VSTM Verastem, Inc. compare | 8.0× |
| INBX Inhibrx Biosciences, Inc. | 439× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)